Skip to main content
Premium Trial:

Request an Annual Quote

LifeCodexx Validates T21 Test as it Completes Regulatory Approval to Launch as IVD

Premium

This story was originally published on April 27.

GATC Biotech subsidiary LifeCodexx has completed the clinical validation of its sequencing-based prenatal trisomy 21 test, Praena Test, and is in the process of gaining regulatory approval to launch the test as an in vitro diagnostic test initially in Germany, Switzerland, Austria, and Liechtenstein.

LifeCodexx's trisomy 21 test is based on the same technology as Sequenom's MaterniT21 Plus test, from whom LifeCodexx licensed intellectual property to commercialize the test in Europe (CSN 8/17/2011).

Unlike MaterniT21 Plus, which analyzes trisomy 21, 13, and 18, the Praena Test evaluates only trisomy 21. Additionally, LifeCodexx validated the test to multiplex 12 samples at once, compared to Sequenom, which runs its test as a 4-plex. Like Sequenom, the test is run on Illumina's HiSeq 2000.

The study analyzed two methods of collecting blood — using conventional blood collection tubes and LifeCodexx's proprietary blood collection tubes — and found that the proprietary tubes, which require no prep work at the physicians' site, yielded higher sensitivity and specificity.

Using LifeCodexx's tubes, the test achieved 100 percent sensitivity and specificity, but when conventional blood collection methods were used, sensitivity was 81.8 percent and specificity was 98.7 percent.

For the study, five prenatal centers and university hospitals in Germany and Switzerland recruited 522 maternal samples from high-risk pregnancies, with 42 positive for trisomy 21. Gestational age ranged from 11 weeks to 32 weeks.

The test has the "long-term potential to considerably reduce the number of procedure-related pregnancy losses induced by invasive diagnostic methods," Markus Stumm, of the Berlin Center for Prenatal Diagnosis and Human Genetics, said in a statement.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.